[1. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. Journal of bone and mineral research. 1994; 9(8):1137-1141.10.1002/jbmr.5650090802]Search in Google Scholar
[2. Riggs BL, Melton Iii LJ. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995; 17(5):S505-S511.10.1016/8756-3282(95)00258-4]Open DOISearch in Google Scholar
[3. Rosen CJ, Compston JE, Lian JB. ASBMR primer on the metabolic bone diseases and disorders of mineral metabolism. 2009, John Wiley & Sons.]Search in Google Scholar
[4. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Stracke H. Risk of new vertebral fracture in the year following a fracture. Jama. 2001; 285(3):320-323.10.1001/jama.285.3.320]Search in Google Scholar
[5. Cooper C. The crippling consequences of fractures and their impact on quality of life. The American Journal of Medicine. 1997; 103(2):S12-S19.10.1016/S0002-9343(97)90022-X]Search in Google Scholar
[6. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis International. 2000; 11(7):556-561.10.1007/s00198007007511069188]Open DOISearch in Google Scholar
[7. Sinescu RD, Niculae A, Peride I, Vasilescu F, Bratu OG, Mischianu DL, Checheriţă IA. Uterus neuroendocrine tumor–a severe prognostic factor in a female patient with alcoholic cirrhosis undergoing chronic hemodialysis. Rom J Morphol Embryol. 2015; 56(2):601-605.]Search in Google Scholar
[8. Bratu O, Mischianu D, Spanu D, Barla R, Hoara P, Constantinoiu S. Paraneoplastic Syndrome in Primitive Retroperitoneal Tumours. Chirurgia. 2013; 108:26-31.]Search in Google Scholar
[9. Niculae A, Peride I, Vinereanu V, Radulescu D, Bratu OG, Geavlete BF, Checherita IA. Nephrotic syndrome secondary to amyloidosis in a patient with monoclonal gammopathy with renal significance (MGRS). Rom J Morphol Embryol. 2017; 58(3):1065-1068.]Search in Google Scholar
[10. Niculae A, Peride I, Marinescu-Paninopol A, Vrabie CD, Ginghina O, Jecan CR, Bratu OG. Renal artery bilateral arteriosclerosis cause of resistant hypertension in hemodialysed patients. Rom J Morphol Embryol. 2016; 57(2):591-594.]Search in Google Scholar
[11. Checherita IA, Smarandache D, Radulesc D, Peride I, Bratu O, Ciocâlteu A, Lascar I. Calcific uremic arteriolopathy in hemodialyzed patients. Chirurgia. 2013; 108(5):736-740.]Search in Google Scholar
[12. Radulescu D, Stroescu A, Pricop C, Geavlete B, Negrei C, Bratu O, Vacaroiu IA. Vitamin K Influence on Cardiovascular Mortality in Chronic Hemodialysed Patients. Revista de Chimie. 2017; 68(1):52-54.10.37358/RC.17.1.5387]Search in Google Scholar
[13. Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: a review. Journal of Women's Health. 2014; 23(7):563-572.10.1089/jwh.2013.4611408902124766381]Search in Google Scholar
[14. Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthopedic Clinics. 2013; 44(2):125-135.10.1016/j.ocl.2013.01.005]Search in Google Scholar
[15. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Ichimura S. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). Journal of Bone and Mineral Metabolism. 2005; 23(2):97-104.10.1007/s00774-004-0547-6]Search in Google Scholar
[16. Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F. Development and use of FRAX® in osteoporosis. Osteoporosis International. 2010; 21(2):407-413.10.1007/s00198-010-1253-y20464374]Open DOISearch in Google Scholar
[17. Daroszewska A. Prevention and treatment of osteoporosis in women: an update. Obstetrics, Gynaecology & Reproductive Medicine. 2012; 22(6):162-169.10.1016/j.ogrm.2012.02.007]Search in Google Scholar
[18. Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart. 2012; 98(12):920-925.10.1136/heartjnl-2011-30134522626900]Open DOISearch in Google Scholar
[19. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. 2005.10.3310/hta922015929857]Search in Google Scholar
[20. Baim S, Miller PD. Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. Journal of Bone and Mineral Research. 2009; 24(4):561-574.10.1359/jbmr.09020319257812]Open DOISearch in Google Scholar
[21. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine. 2006; 144(10):753-761.10.7326/0003-4819-144-10-200605160-0000916702591]Search in Google Scholar
[22. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Jama. 2011; 305(8):783-789.10.1001/jama.2011.19021343577]Search in Google Scholar
[23. Grimer RJ. Denosumab: a drug that you may be hearing a lot more about. Bone&Joint 360. 2013; 2(5):43-44.10.1302/2048-0105.25.360183]Search in Google Scholar